Interleukin-12: Biological Properties and Clinical ApplicationMichele Del Vecchio, Andrea Anichini, Emilio Bajetta et al.|Clinical Cancer Research|2007Cited by 606
756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)Jonathan W. Riess, Pilar Garrido, Jaime Rubio et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1